AR115416A1 - Moduladores de la expresión de apol1 - Google Patents
Moduladores de la expresión de apol1Info
- Publication number
- AR115416A1 AR115416A1 ARP190101365A ARP190101365A AR115416A1 AR 115416 A1 AR115416 A1 AR 115416A1 AR P190101365 A ARP190101365 A AR P190101365A AR P190101365 A ARP190101365 A AR P190101365A AR 115416 A1 AR115416 A1 AR 115416A1
- Authority
- AR
- Argentina
- Prior art keywords
- segment
- modified oligonucleotide
- linked nucleosides
- cet
- nucleoside
- Prior art date
Links
- 102100030762 Apolipoprotein L1 Human genes 0.000 title abstract 3
- 101100323521 Homo sapiens APOL1 gene Proteins 0.000 title abstract 3
- 239000002777 nucleoside Substances 0.000 abstract 9
- 125000003835 nucleoside group Chemical group 0.000 abstract 5
- 108091034117 Oligonucleotide Proteins 0.000 abstract 4
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 abstract 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 abstract 1
- 229940104302 cytosine Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862674865P | 2018-05-22 | 2018-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115416A1 true AR115416A1 (es) | 2021-01-13 |
Family
ID=68613945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101365A AR115416A1 (es) | 2018-05-22 | 2019-05-22 | Moduladores de la expresión de apol1 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10927377B2 (enExample) |
| EP (1) | EP3799570A4 (enExample) |
| JP (3) | JP7247227B2 (enExample) |
| KR (2) | KR20250153881A (enExample) |
| CN (3) | CN118127019A (enExample) |
| AR (1) | AR115416A1 (enExample) |
| AU (2) | AU2019274461B2 (enExample) |
| BR (1) | BR112020023436A2 (enExample) |
| CA (1) | CA3099750A1 (enExample) |
| CL (1) | CL2020003010A1 (enExample) |
| CO (1) | CO2020015377A2 (enExample) |
| CR (1) | CR20200631A (enExample) |
| EA (1) | EA202092748A1 (enExample) |
| EC (1) | ECSP20082339A (enExample) |
| IL (2) | IL316397A (enExample) |
| JO (1) | JOP20200291A1 (enExample) |
| MA (1) | MA53924A (enExample) |
| MX (2) | MX2020012497A (enExample) |
| MY (1) | MY200352A (enExample) |
| NI (1) | NI202000085A (enExample) |
| PE (1) | PE20211397A1 (enExample) |
| PH (1) | PH12020551995A1 (enExample) |
| SG (1) | SG11202011397QA (enExample) |
| TW (2) | TW202430638A (enExample) |
| UA (1) | UA128819C2 (enExample) |
| WO (1) | WO2019226611A1 (enExample) |
| ZA (1) | ZA202007537B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE49076E1 (en) | 2010-04-18 | 2022-05-17 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating renal disease |
| CN118127019A (zh) | 2018-05-22 | 2024-06-04 | Ionis制药公司 | Apol1表达的调节剂 |
| LT3897833T (lt) | 2018-12-17 | 2026-04-27 | Vertex Pharmaceuticals Incorporated | Apol1 inhibitoriai ir jų panaudojimo būdai |
| EP4097083A1 (en) | 2020-01-29 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| JP2023530271A (ja) | 2020-06-12 | 2023-07-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｐｏｌ１の阻害剤及びこれを使用する方法 |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| MX2024008868A (es) | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
| US20260055083A1 (en) * | 2022-08-19 | 2026-02-26 | Maze Therapeutics, Inc. | Apol1 inhibitors and methods of use |
| WO2025242689A1 (en) | 2024-05-21 | 2025-11-27 | Astrazeneca Ab | Methods for treating apol1-mediated kidney disease |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020082401A1 (en) | 1994-12-15 | 2002-06-27 | Yeda Research And Development Company | Modulators of the function of FAS/APO1 receptors |
| US6833361B2 (en) * | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| AU2126502A (en) | 2000-10-03 | 2002-04-15 | Gene Logic, Inc. | Gene expression profiles in granulocytic cells |
| USH2191H1 (en) | 2000-10-24 | 2007-06-05 | Snp Consortium | Identification and mapping of single nucleotide polymorphisms in the human genome |
| US20070054278A1 (en) | 2003-11-18 | 2007-03-08 | Applera Corporation | Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof |
| US20050171044A1 (en) | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| EP1799859B1 (en) | 2004-09-17 | 2014-07-02 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| EP1867338A1 (en) | 2006-05-30 | 2007-12-19 | Université Libre De Bruxelles | Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| MY188457A (en) | 2008-10-03 | 2021-12-10 | Opko Curna Llc | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
| JP6099868B2 (ja) | 2008-12-04 | 2017-03-22 | クルナ・インコーポレーテッド | サーチュイン１（ｓｉｒｔ１）に対する天然アンチセンス転写物の抑制によるサーチュイン１関連疾患の治療 |
| US20120128682A1 (en) | 2009-08-18 | 2012-05-24 | Universite Libre De Bruxelles | Apolipoprotein l- i variants and their use |
| AU2010319314C1 (en) | 2009-11-13 | 2016-09-01 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| EP2515947B1 (en) | 2009-12-23 | 2021-10-06 | CuRNA, Inc. | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
| US9023355B2 (en) | 2010-04-13 | 2015-05-05 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating renal disease |
| US20120003644A1 (en) | 2010-06-07 | 2012-01-05 | Rappaport Family Institute For Research In The Medical Sciences | Methods and kits for determining predisposition to develop kidney diseases |
| AU2013216852A1 (en) * | 2012-02-08 | 2014-08-21 | Isis Pharmaceuticals, Inc. | Methods and compositions for modulating Factor VII expression |
| RU2624028C2 (ru) | 2012-05-24 | 2017-06-30 | Ионис Фармасьютикалз, Инк. | Способы и композиции для модулирования экспрессии аполипопротеина (а) |
| CN104781275A (zh) | 2012-11-16 | 2015-07-15 | 默沙东公司 | 修饰的apol1多肽 |
| US10130632B2 (en) * | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| JP2016522675A (ja) | 2013-03-14 | 2016-08-04 | ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． | 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター |
| GB201311057D0 (en) | 2013-06-21 | 2013-08-07 | Univ Greenwich | Antisense oligonucleotide compositions |
| TWI702046B (zh) * | 2013-07-19 | 2020-08-21 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| WO2015136509A2 (en) | 2014-03-14 | 2015-09-17 | Genesis Theranostix Korlatolt Felelossegu Tarsasag | Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy |
| SI3119888T1 (sl) | 2014-03-19 | 2021-11-30 | Ionis Pharmaceuticals, Inc. | Sestavki za moduliranje izražanja ataksina 2 |
| EP3020813A1 (en) | 2014-11-16 | 2016-05-18 | Neurovision Pharma GmbH | Antisense-oligonucleotides as inhibitors of TGF-R signaling |
| TW201718010A (zh) * | 2015-06-19 | 2017-06-01 | 健臻公司 | 治療原發性局部節段性腎小球硬化症之方法 |
| WO2017004243A1 (en) | 2015-06-29 | 2017-01-05 | Caris Science, Inc. | Therapeutic oligonucleotides |
| HK1251624A1 (zh) * | 2015-09-24 | 2019-02-01 | Ionis Pharmaceuticals, Inc. | Kras表达的调节剂 |
| CN118127019A (zh) | 2018-05-22 | 2024-06-04 | Ionis制药公司 | Apol1表达的调节剂 |
-
2019
- 2019-05-21 CN CN202410386618.XA patent/CN118127019A/zh active Pending
- 2019-05-21 IL IL316397A patent/IL316397A/en unknown
- 2019-05-21 US US16/418,060 patent/US10927377B2/en active Active
- 2019-05-21 WO PCT/US2019/033244 patent/WO2019226611A1/en not_active Ceased
- 2019-05-21 CA CA3099750A patent/CA3099750A1/en active Pending
- 2019-05-21 PE PE2020001880A patent/PE20211397A1/es unknown
- 2019-05-21 KR KR1020257034730A patent/KR20250153881A/ko active Pending
- 2019-05-21 JP JP2020565431A patent/JP7247227B2/ja active Active
- 2019-05-21 CN CN202410386621.1A patent/CN118127020A/zh active Pending
- 2019-05-21 IL IL278785A patent/IL278785B2/en unknown
- 2019-05-21 MY MYPI2020006084A patent/MY200352A/en unknown
- 2019-05-21 EP EP19807789.3A patent/EP3799570A4/en active Pending
- 2019-05-21 CN CN201980033544.9A patent/CN112423792B/zh active Active
- 2019-05-21 TW TW113114934A patent/TW202430638A/zh unknown
- 2019-05-21 KR KR1020207036583A patent/KR102874776B1/ko active Active
- 2019-05-21 CR CR20200631A patent/CR20200631A/es unknown
- 2019-05-21 JO JOP/2020/0291A patent/JOP20200291A1/ar unknown
- 2019-05-21 SG SG11202011397QA patent/SG11202011397QA/en unknown
- 2019-05-21 BR BR112020023436-2A patent/BR112020023436A2/pt unknown
- 2019-05-21 MA MA053924A patent/MA53924A/fr unknown
- 2019-05-21 TW TW108117504A patent/TWI841564B/zh active
- 2019-05-21 MX MX2020012497A patent/MX2020012497A/es unknown
- 2019-05-21 AU AU2019274461A patent/AU2019274461B2/en active Active
- 2019-05-21 UA UAA202007818A patent/UA128819C2/uk unknown
- 2019-05-21 EA EA202092748A patent/EA202092748A1/ru unknown
- 2019-05-22 AR ARP190101365A patent/AR115416A1/es unknown
-
2020
- 2020-09-18 US US17/025,239 patent/US11525136B2/en active Active
- 2020-11-18 PH PH12020551995A patent/PH12020551995A1/en unknown
- 2020-11-19 CL CL2020003010A patent/CL2020003010A1/es unknown
- 2020-11-20 MX MX2025003294A patent/MX2025003294A/es unknown
- 2020-11-20 NI NI202000085A patent/NI202000085A/es unknown
- 2020-12-03 ZA ZA2020/07537A patent/ZA202007537B/en unknown
- 2020-12-09 CO CONC2020/0015377A patent/CO2020015377A2/es unknown
- 2020-12-18 EC ECSENADI202082339A patent/ECSP20082339A/es unknown
-
2022
- 2022-11-08 US US18/053,447 patent/US12168766B2/en active Active
-
2023
- 2023-03-15 JP JP2023040313A patent/JP7645301B2/ja active Active
-
2024
- 2024-11-06 JP JP2024194079A patent/JP2025013513A/ja active Pending
- 2024-11-07 US US18/939,901 patent/US20250066785A1/en active Pending
-
2025
- 2025-10-31 AU AU2025259982A patent/AU2025259982A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113214A1 (es) | Moduladores de la expresión de pcsk9 | |
| MX2023001538A (es) | Composiciones y metodos para inhibir la expresion de lpa. | |
| AR106135A1 (es) | Moduladores de la expresión del sarcoma de la rata de kirsten (kras) | |
| PE20181267A1 (es) | Modulacion de la expresion del virus de la hepatitis b (vhb) | |
| PE20190354A1 (es) | Moduladores del factor del complemento b | |
| IL273875B1 (en) | Methods and compositions for inhibiting expression of ldha | |
| CO6241169A2 (es) | Metodos para el tratamiento de hipercolesterolemia | |
| PE20181085A1 (es) | Composiciones y metodos para modular la expresion de angiotensinogeno | |
| RU2011119479A (ru) | Модуляция экспрессии фактора 11 | |
| PE20191351A1 (es) | Tratamiento aav de la enfermedad de huntington | |
| RU2016140897A (ru) | Композиции для модуляции экспрессии атаксина 2 | |
| CL2023000394A1 (es) | Análogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-il)arilsufonamida sustituidos como moduladores de la proteína cereblon | |
| AR108038A1 (es) | Oligonucleótidos para reducir la expresión de pd-l1 (ligando de muerte programada-1) | |
| ES2539790T3 (es) | Métodos y composiciones para modular c-met hiperestabilizado | |
| AR069821A1 (es) | Composiciones y metodos de uso de la interferencia de arn para el control de nematodos | |
| CL2013003105A1 (es) | Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer | |
| BR0008742A (pt) | Método e dispositivo para a produção de artigos de cerdas e artigos de cerdas produzidas segundo o método | |
| DE60143901D1 (de) | Antisense-modulation der clusterinexpression | |
| AR081209A1 (es) | Tratamiento de enfermedades relacionadas con la proteina 11 del tipo linfoma 2 de celulas b, (bcl2, bcl2l11) mediante la inhibicion del transcripto antisentido natural a bcl2l11 | |
| PE20241340A1 (es) | Composiciones moduladoras de complemento del factor b y metodos de uso de estas | |
| PH12021551025A1 (en) | 5-halouracil-modified micrornas and their use in the treatment of cancer | |
| BR112019008810A2 (pt) | micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer | |
| PE20250156A1 (es) | Composiciones y metodos para inhibir el factor b del complemento | |
| PE20242356A1 (es) | Composiciones moduladoras de angiotensinogeno y metodos de utilizacion de estas | |
| PE20212248A1 (es) | Molecula oligomerica de acido nucleico y uso de esta |